RAPH (Raphael Pharmaceutical) Stock Based Compensation: $0.05 Mil (TTM As of Mar. 2026)


RAPH Raphael Pharmaceutical Inc RAPH
37 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Stock Based Compensation?

Raphael Pharmaceutical RAPH 37 Stock Based Compensation is $0.05 Mil as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Raphael Pharmaceutical's Stock Based Compensation for the three months ended in Mar. 2026 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.05 Mil.

Raphael Pharmaceutical Stock Based Compensation Related Terms

Raphael Pharmaceutical Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Stock Based Compensation Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 2.29 0.20 0.39 0.25

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.01 0.04 0.00 0.00
RAPH
37GF Score
Raphael Pharmaceutical Inc RAPH
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

What does a Stock Based Compensation of $0.05 Mil mean?
Raphael Pharmaceutical (RAPH) has a Stock Based Compensation of $0.05 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Stock Based Compensation too high?
Raphael Pharmaceutical's current Stock Based Compensation is $0.05 Mil. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Stock Based Compensation compare to TXMD and AYTU?
Raphael Pharmaceutical's Stock Based Compensation of $0.05 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Stock Based Compensation is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Stock Based Compensation of $0.05 Mil. The current Stock Based Compensation is $0.05 Mil. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Stock Based Compensation is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score

Get the complete analysis for RAPH

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price